Holistic
12 april 2021
ICRA
ICRA (Improve Checkpoint-blockade Response in Advanced urothelial cancer), an adaptive clinical study to determine efficacy of combining weekly paclitaxel with tremelimumab +/- durvalumab (MEDI4736) Protocolnummer: ESR-18-13667 EudraCT nummer:...
IMA203-301
28 juli 2026
Dit is een prospectieve, multicenter, open-label, gerandomiseerde fase 3-studie waarin de werkzaamheid, verdraagbaarheid en veiligheid van IMA203 wordt vergeleken met een door de onderzoeker gekozen standaardbehandeling bij patiënten...
IMA402-101 studie
25 september 2025
A phase I/II First In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific Tcell-Engaging Receptor Molecule (TCER) targeting PRAME, in Patients with...
ImaGelato
12 april 2021
Can 89Zr-atezolizumab PET scan identify patients with metastatic invasive lobular breast cancer who will respond to chemotherapy-immune checkpoint inhibition? ImaGelato Protocolnummer: 201900180 Eudractnummer: 2019-001197-28 METc nummer: 2019/232 Onderzoekscode:...
Imatinib TUNE
15 september 2022
IMGN151-1001
23 juli 2025
Open-label, fase 1- dosisescalatie en uitbreidingsstudie van IMGN151 (een anti-FRα geneesmiddel-antilichaamconjugaat) bij volwassen patiënten met recidiverende gynaecologische kankers. Samenvatting De studie betreft een Fase1, open-label dosis-escalatie- en uitbreidingsstudie,...
IMPACT – Breast
12 april 2021
Towards patient tailored cancer treatment supported by molecular imaging IMPACT: IMaging PAtients for Cancer drug selecTion – Metastatic Breast Cancer METcnummer: 2013/146 EudraCT nummer: 2013-000551041 Samenvatting Mogelijk zijn...
Impact – CRC
Image guided treatment optimalization with cetuximab for patients with metastatic colorectal cancer: IMPACT – CRC EudraCT nummer: 2013-002023-41 METc nummer: 2013/452 Onderzoekscode: ON41 Samenvatting Bij uitgezaaide dikke darmkanker...
IMPACT-RCC
Watchful waiting in patients with good and intermediate risk metastatic renal cell carcinoma; an imaging guided observational approach. METcnummer: 2014.176 Onderzoekscode: O126 Samenvatting In een deel van de...
IMVigor010 (WO29636)
A phase III, open-label, multicenter, randomized study of atezolizumab (anti-PDL-L1 antibody) versus observation as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma after surgical resection Protocolnummer: WO29636...
Inflame
Towards optimal treatment of inflammatory breast cancer patients Protocolnummer: BOOG 2014-05 METc nummer: 2014/345 Onderzoekscode: Samenvatting Inflammatoir mammacarcinoom (ook wel IBC, afgekort van “inflammatory breast cancer”) is...
Inflame
Inhibrx Ph1 INBRX-109
9 mei 2025
InvestiCAT-iPSC
6 mei 2021
Investigating cardiovascular adverse events related to cancer treatment: a study of extreme toxicity using induced pluripotent stem cells. METc nummer: 2017/395 Onderzoekscode t.b.v. borstkanker deel: O234 Samenvatting De...
Knowledge and attitudes regarding healthy lifestyle
12 april 2021
Knowledge and attitudes regarding healthy lifestyle and health behavior change in cancer patients and their partners; a pilot study Protocolnummer: 201501074 METc nummer: 2015.495 Samenvatting Kankerpatiënten krijgen tijdens...
Knowledge and attitudes regarding healthy lifestyle
Knowledge and attitudes regarding healthy lifestyle
KO-TIP-007
The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS...
KO-TIP-007
KRT-232-103
20 september 2022
A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients with p53 Wild-Type (p53WT)Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy,...
Kwaliteit van leven immunotherapie
12 april 2021
Quality of life, cognitive function, and physical fitness of melanoma and NSCLC patients surviving more than 2 years after immune checkpoint inhibitor therapy Protocolnummer: 201800146 Eudract nummer: METc...
Kwaliteit van leven immunotherapie
Libretto-531
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer...
M12-914
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer Protocolnummer: M12-914 EudraCT...